current
bcg
bacillu
vaccin
recommend
three
billion
dose
administ
sinc
introduct
bcg
prepar
strain
attenu
live
bovin
tuberculosi
bacillu
mycobacterium
bovi
lost
virul
human
special
subcultur
artifici
medium
howev
although
protect
newborn
children
sever
form
tb
efficaci
pulmonari
tb
adolesc
adult
far
optim
protect
rate
vari
accord
geograph
area
new
vaccin
vaccin
strategi
develop
includ
use
attenu
live
mycobacteria
recombin
microorgan
subunit
primeboost
strategi
base
success
administr
certain
mycobacteri
antigen
two
differ
vaccin
vector
dna
vaccin
variou
type
vaccin
differ
elicit
immun
respons
live
attenu
vaccin
lav
mimic
natur
infect
without
virul
trigger
activ
innat
immun
system
pamp
follow
inject
lav
rapidli
dissemin
throughout
vascular
network
drain
lymph
node
therefor
rout
applic
lav
specif
influenc
immun
respons
lav
also
need
adjuv
possess
natur
intrins
adjuv
safeti
concern
exist
replic
compet
possibl
recombin
wild
type
nonliv
vaccin
inactiv
recombin
vaccin
whether
contain
protein
carbohydr
less
effect
absenc
replic
vaccineinduc
immun
reaction
remain
limit
therefor
rout
vaccin
influenc
efficaci
durat
immun
reaction
nonliv
vaccin
induc
lower
antibodi
respons
gener
cytotox
lymphocyt
activ
compar
lav
nonliv
vaccin
regard
biolog
safe
fig
biolog
barrier
overcom
dna
vaccin
way
cell
nucleu
plasmid
dna
translat
cellular
mrna
deliveri
plasmid
dna
target
tissu
eg
skelet
muscl
skin
lot
tissu
nucleas
attack
degrad
larg
amount
applic
dna
also
extracellular
matrix
collagen
hyaluron
acid
influenc
passag
applic
site
cell
membran
small
portion
estim
still
intact
plasmid
dna
cross
cell
membran
phagocytosi
pinocytosi
insid
cell
rout
toward
nucleu
also
spike
exo
endonucleas
probabl
estim
success
activ
transport
nucleu
pore
membran
npc
small
particl
kda
abl
pass
nuclear
pore
complex
npc
passiv
diffus
larger
particl
need
support
carrier
protein
effici
passag
complex
enorm
loss
plasmid
dna
variou
tool
develop
protect
plasmid
dna
thu
increas
efficaci
encapsul
liposom
bind
dna
dendrim
figur
illustr
passag
plasmid
dna
extracellular
matrix
ecm
nucleu
wherea
human
medicin
clinic
trial
dna
vaccin
still
ongo
without
regist
product
market
first
approv
dna
vaccin
veterinarian
medicin
avail
sinc
discuss
first
veterinarian
dna
vaccin
develop
hors
davi
bs
wnv
gies
eav
today
number
current
clinic
trial
worldwid
veterinari
dna
vaccin
unmanag
probabl
speci
hit
plasmid
dna
contain
cdna
human
tyrosinas
hutyr
tumor
antigen
ta
nonmut
differenti
antigen
specif
melanoma
tyrosinas
glycoprotein
essenti
process
melanin
synthesi
fig
like
ta
tyrosinas
overexpress
tumor
cell
therefor
ideal
target
cancer
therapi
normal
strong
immun
reaction
bodi
protein
immun
dog
xenogen
hutyr
cdna
break
immun
toler
self
tumor
differenti
antigen
induc
antibodi
cytotox
cell
respons
melanoma
cell
tyrosinas
highli
conserv
dog
mous
man
recent
clinic
trial
dog
diagnos
stage
ii
iii
canin
oral
melanoma
safeti
efficaci
xenogen
dna
vaccin
investig
dog
receiv
treatment
seri
follow
surgic
remov
primari
tumor
radiotherapi
case
posit
surgic
margin
posit
region
lymph
node
one
dose
contain
dna
given
volum
ml
transderm
rout
via
needlefre
vaccin
devic
booster
immun
given
interv
march
drug
manufactur
receiv
condit
licens
oncept
usda
full
licens
result
xenogen
immun
dog
hutyr
cdna
adjunct
therapi
cmm
demonstr
signific
increas
surviv
time
compar
control
group
none
dog
develop
system
advers
reaction
toxic
seen
overal
safeti
dna
vaccin
confirm
vaccin
develop
repres
tremend
mileston
dna
scienc
technolog
west
nile
viru
wnv
mosquitoborn
member
famili
flavivirida
genu
flaviviru
first
identifi
uganda
africa
positivesens
singlestrand
rna
viru
ssrna
kb
encod
singl
polyprotein
seven
nonstructur
protein
three
structur
protein
rna
strand
held
within
nucleocapsid
wnv
replic
cytoplasm
infect
cell
wnv
zoonot
viru
primari
reservoir
bird
signific
impact
spread
infect
across
countri
contin
differ
speci
describ
carrier
viru
wnv
spread
bird
bird
mosquito
bite
take
blood
meal
bird
infect
viru
bird
speci
get
ill
die
other
clinic
sign
surviv
mosquito
also
capabl
spread
viru
hors
dog
cat
mice
allig
lot
mammal
also
human
onethird
hors
bitten
carrier
mosquito
develop
diseas
die
affect
euthanasia
requir
incub
period
rang
day
hors
becom
ill
vari
symptom
muscl
trembl
skin
twitch
ataxia
sleepi
dull
listless
wnv
may
cross
placenta
mother
gestat
foal
hors
spread
diseas
human
wnv
produc
differ
outcom
human
like
hors
fever
headach
chill
diaphoresi
weak
swollen
lymph
node
drowsi
pain
joint
compar
symptom
influenza
sever
neuroinvas
infect
includ
mening
enceph
surfac
envelop
protein
e
main
target
antibodi
respons
copi
e
protein
matur
wnv
virion
e
function
interact
cell
surfac
fusion
viru
cellular
membran
premembran
protein
prm
cleav
viral
matur
smaller
membran
peptid
express
prm
e
protein
cell
result
format
viruslik
particl
vlp
vlp
share
mani
antigen
structur
properti
fulli
matur
virus
special
interest
vaccin
develop
fig
final
express
plasmid
immun
hors
contain
human
cytomegaloviru
earli
gene
promot
signal
sequenc
japanes
viru
fusion
gene
prm
e
wnv
dna
vaccin
induc
stabl
longlast
complet
immun
respons
month
safe
hors
vaccin
approv
veterinari
use
usda
juli
releas
public
decemb
infecti
hematopoiet
necrosi
ihn
viru
common
viral
pathogen
wild
farm
salmonid
particular
pacif
salmonid
rainbow
trout
atlant
salmon
ihn
viru
enzoot
pacif
northwest
howev
vari
effect
differ
pacif
salmonid
negativesens
singlestrand
ssrna
viru
member
rhabdovirida
famili
genu
novirhabdoviru
rna
genom
nucleotid
long
contain
leader
l
trailer
sequenc
respect
code
region
n
p
g
nv
l
gene
g
encod
surfac
glycoprotein
socal
spike
main
target
immun
respons
ihnv
transmit
follow
shed
viru
fece
urin
sexual
fluid
extern
mucu
direct
contact
close
contact
surround
contamin
water
viru
gain
entri
fish
base
fin
salmon
carnivor
current
fed
meal
produc
catch
wild
fish
marin
organ
perman
origin
possibl
infect
ihnv
clinic
sign
infect
ihnv
includ
anemia
skin
darken
bulg
eye
fade
gill
abdomin
distens
infect
fish
commonli
hemorrhag
sever
area
like
mouth
pector
fin
muscl
near
anu
yolk
sac
fri
diseas
fish
weaken
eventu
float
surfac
water
necrosi
common
kidney
spleen
sometim
liver
mortal
rate
older
fish
kg
tend
rang
smolt
mortal
rate
often
exce
averag
cumul
mortal
follow
outbreak
estim
antigen
viral
surfac
glycoprotein
g
capabl
elicit
neutral
antibodi
product
protect
immun
respons
g
gene
clone
eukaryot
express
vector
insert
intermediateearli
promot
polyadenyl
signal
special
vaccin
prepar
twocompon
vaccin
singl
vaccin
one
plasmid
second
compon
portion
nucleic
acid
sequenc
encod
second
peptid
deriv
fish
pathogen
said
rhabdoviru
result
fusion
second
pathogen
fish
pathogen
eg
isav
ipnv
iridoviru
nnv
spdv
svcv
vhsv
koi
herp
viru
rational
behind
presenc
ihnv
g
protein
boost
immun
respons
second
protein
result
protect
effect
infect
fish
pathogen
vaccin
given
intramuscularli
dosag
left
dorsal
flank
area
dorsal
fin
first
dna
fish
vaccin
licens
canada
veterinari
biolog
section
vb
anim
health
product
divis
canadian
food
inspect
agenc
cfia
also
use
studi
norway
first
report
unit
state
mysteri
socal
coloni
collaps
disord
ccd
decim
bee
coloni
first
observ
winter
without
interrupt
similar
situat
also
given
europ
bee
live
coloni
first
descript
origin
earli
nineteenth
centuri
coloni
loss
known
england
isl
wight
diseas
american
call
phenomenon
disappear
diseas
wherea
coloni
loss
franc
late
call
mysteri
bee
loss
bee
gone
huge
loss
honey
bee
pollin
dramat
impact
agricultur
pollin
crop
nut
fruit
veget
pollin
mellifera
overal
valu
billion
unit
state
billion
eu
bee
coloni
produc
lb
honey
per
day
return
bee
pollin
million
flower
one
keep
mind
besid
european
honey
bee
wild
insect
among
speci
wild
bee
also
great
impact
pollin
seem
effici
pollin
manag
honey
bee
industri
farm
threaten
also
natur
biotop
wild
insect
pollin
total
global
econom
valu
honey
bee
pollin
calcul
billion
billion
food
agricultur
organ
fao
unit
nation
estim
million
manag
honey
bee
coloni
worldwid
besid
profession
agricultur
honey
bee
irreplac
biodivers
organ
appear
evolut
first
flower
plant
exist
sinc
million
year
describ
chap
fig
swine
cattl
bee
europ
north
america
third
import
farm
anim
sinc
formal
list
farm
anim
switzerland
therefor
ccd
econom
also
essenti
global
ecolog
problem
urgent
must
solv
futur
bee
honey
coloni
collaps
disord
last
year
seem
differ
past
outbreak
worker
bee
disappear
instead
die
place
leav
behind
queen
young
bee
high
level
bacteria
virus
fungi
measur
gut
remain
bee
collaps
occur
within
day
differ
theori
discuss
caus
ccd
pesticid
contamin
hotli
debat
interfer
nerv
system
affect
forag
behavior
bee
lead
abandon
hive
fungal
diseas
nosema
spp
known
big
bee
loss
spain
monocultur
genemanipul
crop
electro
smoke
radio
wave
caus
cell
phone
destroy
bee
compass
rigor
travel
truck
crop
crop
usa
februari
profession
us
beekeep
travel
coloni
countri
decemb
therebi
bee
must
reloc
time
europ
bee
coloni
begin
winter
sleep
around
septemb
also
climat
chang
temperatur
sensit
discuss
impact
crop
pollin
ccd
like
caus
combin
factor
ccd
case
overload
bloodsuck
varroa
mite
detect
varroa
current
consid
major
threat
apicultur
infect
diseas
call
varroosi
varroa
destructor
ectoparasit
reddishbrown
flat
shape
mm
long
mm
wide
eight
leg
v
destructor
infest
worker
bee
drone
brood
mite
develop
insid
brood
cell
varroa
real
colossu
compar
size
bee
seen
fig
varroa
mite
belong
scientif
class
arachnida
subclass
acari
speci
describ
alon
mite
mite
prefer
carbohydr
food
meal
crop
hous
dust
mite
feed
flake
shed
human
skin
varroa
mite
prefer
fresh
blood
hemolymph
bee
feed
lb
within
h
varroa
transport
hive
via
piggyback
worker
bee
femal
mite
enter
broad
cell
preferenti
drone
cell
cell
cap
varroa
lay
egg
larva
develop
egg
insect
take
day
bee
larva
mite
hatch
time
newborn
varroa
mite
spread
bee
lifetim
summer
mite
week
wherea
fall
mite
live
sever
month
varroa
reproduc
honey
bee
thu
consid
harmless
insect
varroa
diseas
global
pest
devast
effect
bee
fig
varroa
may
consid
isol
agent
diseas
mortal
adult
bee
brood
must
consid
context
secondari
viral
infect
least
variou
virus
abl
infect
honey
bee
mostli
ssrna
virus
eight
virus
known
associ
varroa
mite
acut
bee
paralysi
viru
abpv
black
queen
cell
viru
bqcv
chronic
bee
paralysi
viru
cbpv
deform
wing
viru
dwv
kashmir
bee
viru
kbv
sacbrood
bee
viru
sbv
cloudi
wing
viru
cwv
slow
bee
paralysi
viru
sbpv
number
natur
synthet
chemic
commerci
avail
control
varroa
infest
first
compound
bromopropyl
fluvalin
pyrethroid
insecticid
make
long
stori
short
varroa
mite
becam
resist
one
product
given
chemic
class
resist
entir
class
sever
relat
synthet
product
also
use
natur
product
formic
acid
miner
oil
thymol
partial
tempor
effect
show
advers
effect
success
chemic
treatment
mite
quickli
develop
resist
chemic
basic
differ
insect
vertebr
immun
miss
highli
specif
antigen
respons
acquir
immun
system
insect
nevertheless
million
year
evolut
insect
develop
power
defens
strategi
bacteria
fungi
virus
parasit
protect
primit
immun
system
insect
success
colon
terrestri
ecosystem
insect
innat
immun
show
mani
similar
vertebr
human
innat
immun
multifacet
involv
humor
cellular
compon
insight
insect
immun
provid
drosophila
melanogast
research
key
mechan
also
observ
honey
bee
humor
system
respons
bacteri
fungal
infect
control
antimicrobi
peptid
amp
circul
receptor
sens
danger
signal
activ
toll
pathway
wherea
membranebound
receptor
activ
imd
pathway
pathway
lead
transloc
nfkblike
transcript
factor
product
amp
nfkb
respons
element
detect
promot
region
diptericin
gene
cellular
immun
respons
mediat
special
blood
cell
hemocyt
plasmatocyt
crystal
cell
lamellocyt
plasmatocyt
repres
major
hemocyt
express
phagocyt
receptor
patrol
bodi
clear
microorgan
cell
debri
signal
infect
fat
bodi
bee
genom
complet
sequenc
express
plasmid
construct
cmv
promot
surprisingli
bee
insect
specif
promot
essenti
drive
express
protein
enhanc
green
fluoresc
protein
egfp
chosen
report
gene
insert
multipl
clone
site
togeth
enhanc
element
plasmid
construct
produc
e
coli
highli
purifi
standard
techniqu
european
honey
bee
api
mellifera
obtain
local
beekeep
cultiv
lab
condit
varroa
mite
collect
infest
bee
oral
vaccin
egfp
plasmid
oper
feed
bee
mix
solut
sugar
plasmid
dna
vaccin
sugar
standard
sugar
solut
made
beekeep
normal
food
winter
bee
day
onset
feed
measur
express
egfp
immunofluoresc
western
blot
analysi
egfp
antibodi
day
clear
egfp
signal
detect
thorax
especi
malpighian
tubul
control
bee
fed
dna
lack
report
show
signal
parallel
control
experi
transform
e
coli
done
studi
possibl
egfp
express
gut
bacteria
instead
bee
cell
egfp
signal
detect
transform
bacteria
surprisingli
found
egfp
signal
day
varroa
mite
suck
hemolymph
bee
fed
vaccin
sugar
solut
signal
control
mite
infest
control
bee
feed
plasmid
dna
result
express
report
gene
differ
bee
tissu
period
sever
day
final
varroa
absorb
protein
via
bloodsuck
bee
blood
carri
arteri
vein
flow
loos
around
bodi
egfp
signal
detect
either
honey
stomach
fece
figur
illustr
egfp
passag
bee
bodi
toward
varroa
mite
start
simpl
idea
biochemistri
eukaryot
cell
remain
irrespect
organ
differ
given
configur
immun
system
mean
insect
success
fight
parasit
infect
differ
weapon
cell
b
cell
consequ
antibodi
memori
abl
stimul
target
immun
gene
bee
measur
insect
typic
immun
respons
standard
plasmid
dna
vaccin
first
develop
hors
bridg
evolut
fish
insect
mammal
vaccin
type
abl
job
fascin
biolog
polyribosylribitol
phosphat
prp
capsul
haemophilu
influenza
type
b
hib
major
virul
factor
organ
prp
cellindepend
antigen
character
eg
induct
poor
antibodi
respons
less
infant
children
inabl
induc
booster
respons
polysaccharid
vaccin
base
prp
alon
develop
coval
linkag
prp
cell
depend
protein
antigen
conjug
vaccin
creat
overcom
cell
independ
characterist
prp
present
three
differ
licens
protein
carrier
link
prp
hboc
diphtheria
crm
protein
mutant
corynebacterium
linkag
spacerhbomp
outer
membran
protein
omp
neisseria
meningitidi
linkag
spacerprpd
diphtheria
toxoid
linkag
spacer
hib
conjug
vaccin
differ
protein
carrier
polysaccharid
size
method
chemic
conjug
includ
use
spacer
prp
protein
carrier
standard
chemic
conjug
polysaccharid
protein
illustr
fig
subunit
vaccin
offer
greater
safeti
intrins
poorli
immunogen
strong
adjuv
essenti
boost
activ
immun
respons
first
defin
caus
agent
bacillari
dysenteri
shiga
japan
shigella
gramneg
bacillu
noncapsul
nonmotil
diagnosi
gener
base
symptom
sinc
bloodi
mucoid
stool
indic
shigella
infect
howev
sever
diarrheal
infect
caus
microorgan
share
symptom
enteroinvas
e
coli
campylobact
among
other
sole
analysi
symptom
insuffici
accur
diagnosi
therefor
clinic
diagnosi
must
complement
microbiolog
isol
cultur
shigella
transmit
rout
consumpt
contamin
food
water
follow
ingest
acidtoler
shigella
pass
stomach
small
intestin
larg
intestin
fig
taken
cell
transcytos
basolater
face
colon
epithelium
present
resid
macrophag
wherein
ipab
type
three
secret
system
induc
apoptosi
caspas
activ
therebi
escap
kill
macrophag
shigella
invad
epitheli
cell
use
creat
transloc
pore
host
cell
membran
initi
orchestr
flow
effector
host
cell
cytoplasm
induc
actin
rearrang
ultim
result
uptak
bacteria
insid
shigella
quickli
escap
vacuol
replic
move
cytoplasm
via
actinbas
motil
manner
shigella
form
protrus
neighbor
uninfect
cell
result
vacuol
quickli
lyse
complet
process
intercellular
spread
gene
associ
encod
plasmid
highli
conserv
among
shigella
speci
heart
type
three
secret
apparatu
compos
basal
bodi
similar
flagellar
system
extracellular
needl
invas
plasmid
antigen
ipad
kda
protein
form
pentamer
ring
tip
needl
control
secret
effector
protein
environment
sensor
mobil
ipab
tip
complex
ipab
kda
transloc
form
ring
atop
ipad
ring
respons
host
cell
contact
contact
requir
mobil
ipac
needl
tip
format
complet
unidirect
conduit
bacteri
cytoplasm
host
cell
cytoplasm
initi
inflamm
invas
process
occur
exclus
basolater
side
host
cell
highlight
import
previou
step
macrophag
subvers
shigella
colon
gut
shigellosi
strictli
human
diseas
basi
restrict
unknown
complic
abil
investig
pathogenesi
shigella
howev
sever
anim
model
develop
studi
pathogenesi
shigella
result
immun
respons
shigella
antigen
protect
efficaci
candid
vaccin
shigellosi
mous
lethal
pulmonari
challeng
mani
recent
vaccin
develop
effort
test
mous
lethal
pulmonari
model
model
high
dose
virul
shigella
administ
mice
intranas
mous
colon
infect
anoth
mous
model
recent
develop
involv
use
streptomycin
clear
intestin
commens
bacteria
treatment
shigella
abl
colon
colon
viabl
shigella
isol
fecal
sampl
day
sereni
test
sereni
test
model
long
use
test
invas
capabl
shigella
model
guinea
pig
inocul
eye
shigella
induc
keratoconjunct
model
allow
examin
shigella
invas
protect
efficaci
candid
vaccin
rabbit
cecal
ligat
model
model
diarrhea
use
indic
infect
diseas
although
model
use
character
interact
shigella
intestin
mucosa
natur
site
infect
difficulti
introduc
surgeri
laboratori
anim
nonhuman
primat
nhp
model
nhp
model
use
defin
abil
vaccin
elicit
immun
respons
protect
rhesu
cynomolgu
monkey
main
advantag
model
shigella
abl
colon
larg
intestin
gener
symptom
bacteria
gener
human
infect
antigenproteosom
antigen
repres
variabl
portion
shigella
lp
fig
administr
lp
antigen
alon
anim
model
enough
elicit
immun
respons
make
ineffect
immunogen
solv
limit
molecul
use
conjunct
differ
protein
carrier
sever
variant
lpsoantigen
mixtur
develop
character
one
protein
combin
approach
use
flexneri
sonnei
lp
complex
neisseria
meningitidi
outer
membran
protein
proteosom
lp
extract
flexneri
sonnei
hot
phenol
extract
mix
detergentextract
outer
membran
protein
n
meningitidi
complex
separ
free
lp
present
mixtur
gel
filtrat
chromatographi
concept
behind
vaccin
protein
present
n
meningitidi
proteosom
abl
act
carrier
cell
stimul
thu
allow
recognit
lp
outer
membran
vesicl
omv
particl
compos
lp
protein
nucleic
acid
propos
vaccin
formul
particl
purifi
liquid
cultur
boydii
centrifug
subsequ
filter
fig
precis
ident
amount
protein
includ
prepar
current
known
although
presenc
protein
mass
ipab
ipac
ipad
suggest
composit
includ
protein
omv
administ
oral
mice
antibodi
gener
omv
lysat
vaccin
advantag
heterolog
protect
shown
challeng
strain
shigella
serogroup
absenc
adjuv
depend
addit
immun
passiv
transfer
offspr
suggest
protect
mechan
involv
antibodi
rais
possibl
vaccin
use
infant
main
target
popul
shigella
vaccin
use
live
fulli
virul
shigella
formul
process
presenc
lp
lottolot
consist
possibl
downsid
prepar
anoth
vaccin
candid
use
protein
lp
part
formul
invaplex
complex
obtain
aqueou
extract
follow
ion
exchang
chromatographi
fig
precis
composit
extract
complet
character
includ
lp
ipab
ipac
complex
abl
elicit
igg
iga
respons
ipa
protein
well
lp
mice
guinea
pig
addit
protect
shigella
speciesserotyp
use
extract
gener
mous
guinea
pig
challeng
model
two
phase
one
studi
perform
use
invaplex
vaccin
adult
volunt
show
major
side
effect
deliveri
intranas
dose
highest
dose
employ
studi
gener
asc
respons
lp
volunt
advantag
approach
invaplex
addit
adjuv
need
administ
drawback
vaccin
consist
challeng
product
process
includ
cultur
virul
shigella
well
presenc
bacteri
lp
product
intermedi
step
final
formul
anoth
possibl
caveat
uniform
protein
composit
complex
manufactur
lot
final
vaccin
design
protect
multipl
serotyp
solut
possibl
drawback
howev
gener
formul
includ
invaplex
complex
gener
one
particular
serotyp
increas
alreadi
difficult
manufactur
process
would
allow
gener
vaccin
formul
specif
serotyp
preval
particular
region
vaccin
candid
target
conserv
shigella
virul
protein
includ
ipa
protein
fig
recombin
ipab
ipad
express
e
coli
high
level
ipad
easili
purifi
e
coli
cytosol
ipab
must
purifi
complex
cognat
chaperon
ipgc
chaperon
need
maintain
hydrophob
ipab
solubl
state
provid
stabil
ipab
proteolyt
degrad
ipab
purifi
separ
ipgc
low
concentr
deterg
analys
indic
ipab
greater
pure
follow
scheme
final
formul
ipabas
vaccin
also
contain
doubl
mutant
heatlabil
enterotoxin
e
coli
dmlt
adjuv
mechan
protect
vaccin
yet
work
nevertheless
test
mous
lethal
pulmonari
model
exhibit
homolog
protect
flexneri
greater
heterolog
protect
use
sonnei
challeng
experi
igg
mucos
iga
gener
intranas
administr
along
antigenspecif
cell
outer
membran
protein
omp
purifi
flexneri
use
ion
exchang
chromatographi
incub
macrophag
protein
induc
product
nitric
oxid
increas
product
protein
deliv
parenter
five
time
rabbit
give
protect
challeng
flexneri
rabbit
cecal
ligat
model
subsequ
work
use
recombin
protein
purifi
affin
chromatographi
identifi
omp
ompa
part
famili
immunomodul
protein
present
numer
gramneg
bacteria
protein
show
high
protect
efficaci
mous
lethal
pulmonari
model
elicit
serum
igg
mucos
iga
guid
principl
antitick
vaccin
stem
earli
studi
conduct
acquir
host
resist
tick
infest
repeat
exposur
host
tick
tick
organ
homogen
induc
resist
tick
reinfest
degre
resist
may
vari
differ
tick
host
speci
evid
strongli
suggest
natur
resist
tick
infest
develop
base
adapt
immun
respons
mechan
tick
feed
host
vaccin
tick
compon
take
effector
molecul
feed
mediat
deleteri
effect
tick
effect
manifest
reduct
feed
time
tick
mortal
feed
reduc
engorg
weight
reduc
reproduct
capac
adult
femal
egg
laid
tick
fed
vaccin
host
may
also
show
reduc
hatch
rate
overal
result
culmin
reduct
tick
popul
tickborn
diseas
mani
antitick
vaccin
target
identifi
use
convent
immunescreen
techniqu
immun
vertebr
host
tick
homogen
purifi
tick
extract
gener
immun
sera
sera
use
screen
tick
antigen
detect
host
identif
tick
protein
essenti
tick
surviv
use
method
target
antigen
discoveri
made
increasingli
possibl
inform
gather
tick
biolog
avail
genom
sequenc
number
tick
speci
number
candid
discoveri
expand
revers
vaccinolog
use
techniqu
rna
interfer
rnai
use
confirm
import
antitick
vaccin
candid
like
play
role
futur
antitick
vaccin
antigen
discoveri
antitick
vaccin
candid
classifi
two
categori
expos
conceal
antigen
expos
antigen
secret
tick
saliva
attach
feed
host
conceal
antigen
normal
hidden
host
immun
respons
molecular
mimicri
tick
host
compon
observ
vaccin
may
induc
host
sensit
autoimmun
reaction
expos
antigen
use
one
advantag
use
expos
antigen
natur
boost
occur
tick
feed
mechanist
vaccin
expos
antigen
thought
induc
focal
hostil
environ
unsupport
tick
attach
feed
conceal
antigen
come
contact
host
immun
respons
natur
tick
feed
although
often
contain
within
thorac
caviti
tick
salivari
gland
protein
character
conceal
secret
tickfeed
site
one
difficulti
develop
conceal
antitick
vaccin
antigen
must
access
induc
humor
vaccin
respons
often
limit
number
candid
come
prolong
direct
contact
blood
meal
humor
respons
transport
gut
barrier
hemolymph
second
limit
conceal
antigen
relat
natur
boost
immun
respons
antigen
come
contact
immun
respons
within
host
suffici
high
antibodi
level
must
induc
repeat
vaccin
blood
meal
act
carrier
effector
immun
respons
antitick
effect
take
place
longer
period
time
compar
expos
antigen
effect
may
even
extend
beyond
mere
feed
period
inact
stage
digest
moltingegg
lay
take
place
antitick
vaccin
remain
antitick
vaccin
commerci
produc
becom
benchmark
futur
antitick
vaccin
develop
evalu
gutassoci
glycoprotein
first
identifi
r
microplu
although
homologu
tick
speci
sinc
identifi
biolog
function
remain
unknown
although
thought
play
role
digest
blood
meal
r
microplu
express
increas
embryogenesi
reach
highest
level
unf
larva
express
decreas
feed
molt
lowest
level
express
detect
rest
stage
tick
translat
code
sequenc
amino
acid
size
kda
protein
contain
four
potenti
nlink
glycosyl
site
leader
peptid
suggest
transport
cell
surfac
local
studi
shown
molecul
locat
predominantli
microvilli
gut
epitheli
cell
singl
ctermin
transmembran
sequenc
present
unprocess
protein
replac
glycosylphosphatidylinositol
anchor
matur
protein
protein
also
contain
multipl
predict
egf
repeat
rich
cystein
residu
vaccin
perform
mostli
whole
molecul
protect
epitop
well
determin
site
protect
b
cell
epitop
defin
addit
epitop
like
exist
overlap
crossreact
immunereact
epitop
found
r
decoloratu
homologu
vaccin
efficaci
directli
relat
antibodi
titer
abil
control
tick
popul
directli
relat
achiev
strong
antibodi
respons
substanti
animaltoanim
variat
observ
abil
gener
antibodi
titer
like
relat
mhc
class
ii
haplotyp
express
antibodi
cattl
complement
system
taken
blood
meal
antibodi
bind
result
lysi
gut
epitheli
cell
culmin
impair
blood
meal
digest
strong
antibodi
respons
may
induc
tick
mortal
due
blood
leakag
gut
hemolymph
tick
may
turn
reddish
instead
gray
develop
antibodi
respons
cattl
immun
demonstr
fig
recombin
express
attempt
sever
express
system
includ
escherichia
coli
aspergillu
nidulan
aspergillu
niger
pichia
pastori
vaccin
trial
show
vaccin
target
mainli
adult
stage
r
microplu
particularli
number
adult
femal
fulli
engorg
postengorg
mortal
reproduct
capac
adult
r
microplu
femal
affect
term
egglay
capac
hatch
egg
field
situat
vaccin
cattl
reduc
tick
number
within
singl
gener
reduc
reproduct
capac
revers
neg
effect
tick
feed
live
weight
vaccin
anim
averag
increas
live
weight
kg
period
observ
extens
field
trial
cuba
brazil
argentina
mexico
show
control
r
microplu
tick
within
period
importantli
complet
control
acaricideresist
tick
could
accomplish
integr
vaccin
acaricid
use
show
integr
control
system
effect
control
tick
popul
vaccin
also
decreas
amount
acaricid
requir
control
tick
popul
prolong
time
interv
cattl
dip
vaccin
extens
evalu
abil
control
tick
speci
almost
complet
crossprotect
rhipicephalu
annulatu
report
signific
protect
hyalomma
anatolicum
h
dromedarii
r
decoloratu
observ
howev
crossprotect
seen
r
appendiculatu
amblyomma
variegatum
first
laboratori
biosafeti
manual
publish
avail
third
edit
manual
cover
risk
assess
safe
use
recombin
dna
technolog
provid
guidelin
certif
laboratori
primari
factor
consid
risk
assess
fall
main
two
categori
agent
hazard
laboratori
procedur
hazard
four
biosafeti
level
bsl
consist
combin
laboratori
practic
techniqu
safeti
equip
laboratori
facil
measur
bsl
rise
order
danger
work
vector
classifi
requir
biosafeti
program
approv
work
vector
classifi
higher
requir
approv
local
biosafeti
committe
demonstr
adenoviru
follow
im
inject
vector
persist
mainli
near
inject
site
drain
lymph
node
month
low
level
integr
chromosom
dna
observ
calcul
mutat
rate
mutat
per
cell
spontan
mutat
rate
cell
therefor
tenfold
higher
classifi
biosafeti
level
live
vector
abl
stimul
mucos
well
system
humor
cellular
immun
sever
drawback
vector
technolog
use
vector
effect
use
patient
recogn
antibodi
repeat
booster
immun
fail
also
preexist
immun
patient
vector
could
render
vaccin
ineffect
heterolog
primeboost
vector
prime
describ
chap
could
circumv
barrier
lactic
acid
bacteria
gener
recogn
safe
gra
statu
develop
past
decad
potent
adjuv
mucos
deliveri
vaccin
platform
technolog
base
lactobacillu
plantarum
fig
develop
deliv
antigen
plagu
diseas
caus
yersinia
pesti
aerob
nonmotil
gramneg
bacillu
belong
famili
enterobacteriacea
transmit
human
via
fleabit
via
aerosol
droplet
caus
bubon
pneumon
plagu
respect
human
plagu
case
present
one
three
primari
form
bubon
septicem
pneumon
secondari
plagu
septicemia
pneumonia
mening
common
complic
pathogen
pesti
result
impress
abil
overcom
defens
mammalian
host
overwhelm
massiv
growth
plagu
enzoot
rodent
africa
asia
south
america
north
america
pesti
transmit
host
host
flea
via
blood
feed
consumpt
handl
infecti
host
tissu
inhal
infecti
materi
pesti
infect
astonishingli
broad
rang
mammal
use
rat
squirrel
mice
prairi
dog
marmot
gerbil
reservoir
sever
arthropod
vector
transmiss
fig
human
acquir
zoonot
infect
via
atyp
bite
anim
flea
sometim
prompt
anim
death
plagu
flea
seek
new
sourc
blood
infect
flea
come
domest
black
rat
rattu
rattu
brown
sewer
rat
rattu
norvegicu
pesti
cell
spread
site
infect
fleabit
region
lymph
node
grow
high
number
caus
format
bubo
spill
bloodstream
bacteria
remov
liver
spleen
growth
continu
organ
spread
other
caus
septicemia
flea
feed
septicem
anim
complet
infect
cycl
human
bubon
plagu
develop
infect
lung
secondari
pneumon
plagu
lead
aerosol
transmiss
primari
pneumon
plagu
multipl
antibioticresist
strain
pesti
occur
natur
easili
bioengin
thu
plagu
categori
bioterror
agent
need
novel
strategi
prevent
bubon
plagu
classic
form
diseas
patient
usual
develop
symptom
fever
headach
chill
swollen
extrem
tender
lymph
node
bubo
within
day
contact
organ
either
fleabit
exposur
open
wound
infect
materi
primari
septicem
plagu
gener
defin
occur
patient
posit
blood
cultur
palpabl
lymphadenopathi
patient
febril
chill
headach
malais
gastrointestin
disturb
primari
pneumon
plagu
rare
deadli
form
diseas
spread
via
respiratori
droplet
close
contact
ft
infect
individu
progress
rapidli
febril
flulik
ill
overwhelm
pneumonia
cough
product
bloodi
sputum
incub
period
primari
pneumon
plagu
day
gener
patient
develop
secondari
plagu
pneumonia
high
fatal
rate
laboratori
diagnosi
plagu
base
bacteriolog
andor
serolog
evid
sampl
analysi
includ
blood
bubo
aspir
sputum
cerebrospin
fluid
patient
plagu
mening
scrape
skin
lesion
present
stain
techniqu
gram
giemsa
wright
wayson
stain
provid
support
presumpt
confirmatori
evid
plagu
infect
lactic
acid
bacteriabas
vaccin
act
live
attenu
vaccin
without
safeti
concern
lab
gener
recogn
safe
gra
statu
thu
like
caus
harm
product
desir
antigen
lab
occur
three
differ
cellular
locat
intracellular
allow
protein
escap
harsh
extern
environment
condit
gastric
juic
stomach
requir
cellular
lysi
protein
releas
deliveri
extracellular
allow
releas
protein
extern
medium
result
direct
interact
environ
food
product
digest
tract
cell
wall
anchor
combin
advantag
two
locat
ie
interact
cell
wallanchor
protein
environ
addit
protect
proteolyt
degrad
context
sever
studi
compar
product
differ
antigen
lab
use
three
locat
evalu
subsequ
immunolog
impact
studi
demonstr
highest
immun
respons
obtain
cell
wallanchor
antigen
expos
surfac
lab
therefor
recent
lab
vaccin
studi
select
surfac
exposur
antigen
interest
rather
intra
extracellular
product
dendrit
cell
dc
play
central
role
bridg
innat
immun
system
adapt
immun
system
dc
found
throughout
bodi
especi
common
mucos
surfac
singl
layer
epitheli
cell
separ
extern
intern
world
amid
constant
need
particl
exchang
intestin
dendrit
cell
dc
play
key
role
maintain
intestin
homeostasi
well
govern
protect
immun
respons
invad
pathogen
avoid
activ
selfreact
cell
limit
unnecessari
respons
commens
flora
dc
imprint
toler
onto
cell
fig
immaturetyp
dc
enrich
underneath
epithelium
mucos
induct
site
pois
captur
antigen
extend
protrus
epitheli
cell
enabl
direct
sampl
lumin
antigen
upregul
mhc
costimulatori
molecul
matur
dc
convert
highli
effici
antigenpres
cell
success
antigen
present
cell
requir
recognit
cognat
peptid
context
mhc
class
ii
molecul
wherea
epitop
present
mhc
class
molecul
stimul
agspecif
cell
antigen
uptak
occur
dc
chang
phenotyp
express
higher
level
costimulatori
molecul
move
cell
area
induct
site
antigen
present
thu
dc
deriv
cytokin
play
key
role
induct
antigenspecif
effector
th
cell
respons
regard
target
mucos
dc
effect
strategi
induc
mucos
system
immun
respons
abil
lab
persist
gastrointestin
tract
may
critic
import
effect
labbas
vaccin
comparison
persist
lab
strain
l
plantarum
nonpersist
lab
strain
l
lacti
identifi
l
plantarum
effect
elicit
antigenspecif
immun
suggest
persist
promot
immunogen
furthermor
shown
particular
lactobacillu
speci
induc
critic
inflammatori
cytokin
induc
activ
matur
dendrit
cell
also
shown
immatur
dc
effici
captur
lactobacillu
speci
bacteria
activ
human
dc
result
product
proinflammatori
cytokin
like
increas
prolifer
cell
skew
cell
respons
toward
pathway
believ
involv
effect
clearanc
microbi
pathogen
fig
evid
suggest
peptidoglycan
layer
lab
promot
natur
immunoadjuvant
antigen
local
cell
wall
make
access
immun
system
compar
intracellular
secret
protein
leader
peptid
mark
protein
transloc
across
cytoplasm
membran
lipid
modif
major
import
anchor
export
protein
membran
protein
function
shown
lipid
first
amino
acid
matur
borrelia
burgdorferi
ospa
protein
essenti
induc
immun
respons
via
leader
peptid
ospa
target
protein
cell
envelop
lactobacillu
cy
recogn
l
plantarum
cell
wallsort
machineri
lipid
anchor
protein
cell
envelop
end
result
deliveri
system
exert
potent
adjuv
effect
nov
group
genet
divers
rna
virus
belong
genu
noroviru
calicivirida
famili
first
discov
character
prototyp
viru
norwalk
viru
nv
studi
nv
reveal
nov
nonenvelop
virus
rna
genom
surround
round
capsid
protein
shell
approxim
nm
diamet
nov
divid
genogroup
cluster
cluster
genogroup
gi
gii
giii
giv
gv
within
five
genotyp
gi
giv
strain
found
infect
human
exclus
gii
found
human
pig
giii
gv
strain
anim
virus
infect
cattl
murin
speci
respect
current
strain
cluster
gii
gii
preval
nov
human
popul
genom
nov
first
character
nv
contain
singlestrand
positivesens
rna
kb
three
open
read
frame
orf
poli
tail
end
fig
encod
polyprotein
process
viral
proteas
rnadepend
rna
polymeras
approxim
five
nonstructur
protein
includ
nucleosid
triphosphatas
vpg
two
structur
protein
major
minor
capsid
protein
encod
respect
structur
analysi
nov
reveal
viral
capsid
compos
dimer
icosahedr
symmetri
fold
two
domain
shell
domain
respons
initi
capsid
assembl
icosahedr
contact
protrud
domain
p
contain
two
subdomain
enhanc
stabil
capsid
provid
intermolecular
contact
dimer
studi
nv
also
indic
protein
enhanc
express
level
stabil
viral
capsid
nov
requir
extrem
low
infecti
dose
challeng
studi
nv
suggest
probabl
infect
singl
viru
particl
approxim
among
suscept
human
popul
transmit
sever
rout
includ
fecalcontamin
food
water
direct
person
person
contact
indirect
exposur
droplet
contamin
object
infect
person
nov
highli
contagi
spread
rapidli
outbreak
commonli
occur
variou
social
place
set
peopl
share
common
food
water
sourc
close
physic
proxim
cruis
ship
school
militari
unit
nurs
home
daycar
center
hospit
restaur
cater
event
life
cycl
nov
fulli
understood
due
lack
vitro
cell
cultur
system
small
anim
model
infect
failur
nov
replic
mammalian
cell
cultur
due
lack
host
factor
support
intracellular
express
nov
rna
instead
problem
may
lie
step
viral
bind
cellular
receptor
viru
entri
cell
variou
diagnost
method
develop
nov
serum
antibodi
nov
readili
detect
method
littl
clinic
relev
due
crossreact
antibodi
sinc
cultur
system
avail
nov
detect
viru
stool
sampl
becom
prefer
method
diagnosi
tradit
nov
infect
diagnos
detect
viru
immun
transmiss
electron
microscopi
tem
tem
offer
advantag
direct
visual
potenti
respons
viru
particl
stool
sampl
howev
disadvantag
requir
sophist
expens
equip
highli
special
technician
oper
sever
enzymelink
immunosorb
assay
elisa
detect
nov
antigen
later
develop
nov
diagnosi
studi
shown
nov
antigendetect
elisa
high
specif
poor
sensit
like
due
antigen
divers
nov
strain
similar
elisabas
assay
rtpcr
rapid
robust
process
larg
number
sampl
simultan
result
obtain
within
work
day
howev
requir
rna
extract
fecal
sampl
need
expens
equip
skill
worker
oper
therefor
rtpcr
labor
intens
less
econom
elisa
overal
tem
elisa
rtpcrbase
method
advantag
challeng
three
method
detect
differ
compon
viru
therefor
complementari
immunolog
knowledg
nov
mostli
obtain
human
challeng
studi
natur
outbreak
due
lack
small
anim
model
observ
repeat
infect
adult
suggest
scarciti
longterm
immun
virus
howev
studi
show
close
genet
suscept
subject
infect
nov
challeng
support
possibl
longterm
immun
lack
tissu
cultur
system
also
imped
develop
vaccin
nov
fortun
discoveri
spontan
assembl
express
viruslik
particl
vlp
morpholog
antigen
similar
nativ
virus
facilit
vaccin
develop
vlp
combin
best
trait
wholeviru
subunit
antigen
vaccin
develop
vlp
noninfecti
therefor
safer
inactiv
attenu
viru
due
lack
viral
nucleic
acid
genom
importantli
vlp
induc
potent
cellular
humor
immun
respons
without
adjuv
effect
vaccin
subunit
antigen
architectur
mimic
infecti
virus
vlp
produc
recombin
technolog
heterolog
express
system
without
requir
abil
support
viral
replic
particularli
import
nov
cultur
system
develop
support
growth
virus
studi
demonstr
virus
correspond
vlp
particl
size
ideal
dc
macrophag
uptak
initi
antigen
process
thu
particul
natur
vlp
favor
target
relev
apc
optim
induct
cellmedi
immun
respons
vlp
also
present
effici
b
cell
induc
strong
antibodi
respons
like
live
virus
quasicrystallin
surfac
vlp
array
repetit
epitop
present
prime
target
vertebr
b
cell
evolv
specif
recogn
recognit
trigger
crosslink
surfac
membraneassoci
immunoglobulin
ig
b
cell
lead
prolifer
migrat
helpercel
activ
antibodi
product
secret
gener
memori
b
cell
thu
vlp
directli
activ
b
cell
much
lower
concentr
subunit
antigen
induc
high
titer
durabl
b
cell
respons
absenc
adjuv
inher
advantag
vlp
made
one
success
recombin
vaccin
platform
exampl
five
vlpbase
vaccin
hepat
b
viru
hbv
human
papillomaviru
hpv
commerci
licens
demonstr
excel
safeti
profil
longterm
protect
infect
human
vlp
nov
first
produc
insect
cell
use
baculoviru
vector
plant
use
tobamoviru
geminiviru
vector
mammalian
cell
use
venezuelan
equin
enceph
vee
replicon
system
studi
demonstr
express
major
capsid
protein
alon
drive
selfassembl
vlp
morpholog
antigen
resembl
nativ
viru
particl
fig
vlp
gener
three
express
system
similar
structur
nov
vlp
exemplifi
vlp
nv
capsid
protein
nvcp
studi
insect
cellbaculovirusderiv
nvcp
vlp
cryoelectron
microscopi
xray
crystallographi
reveal
nv
capsid
nm
icosahedr
arrang
copi
kda
capsid
protein
organ
dimer
symmetri
dimer
form
two
ident
nvcp
monom
two
differ
dimer
configur
requir
correctli
form
complet
assembl
capsid
nativ
nv
particl
nvcp
also
fold
two
distinct
domain
vlp
domain
form
inner
core
shell
p
domain
protrud
capsid
similarli
subdomain
also
surfaceexpos
region
nv
vlp
may
contain
hbga
neutral
antibodybind
site
determin
strain
specif
similar
vlp
nv
nov
includ
virus
demonstr
shown
four
oral
dose
littl
nvcp
vlp
without
adjuv
trigger
serum
nvspecif
antiigg
respons
major
vlpfed
outbr
mice
system
igg
respons
observ
two
oral
dosag
highest
titer
induc
four
dose
vlp
moreov
mice
dosag
group
develop
nvspecif
intestin
iga
level
total
iga
inclus
mucos
adjuv
cholera
toxin
ct
significantli
chang
number
posit
respond
serum
igg
intestin
iga
significantli
enhanc
amplitud
serum
igg
respons
especi
higher
dose
vlp
thu
nvcp
vlp
clearli
potent
oral
immunogen
induc
system
gut
mucos
antibodi
respons
effect
ga
vaccin
need
broad
antigen
reach
mani
differ
ga
strain
differ
type
circul
popul
induc
immun
respons
potenti
crossreact
self
tissu
protein
ga
protein
major
protect
antigen
ideal
target
vaccin
develop
howev
contain
heart
tissu
crossreact
epitop
particularli
conserv
region
evid
suggest
crossreact
cell
especi
play
pivot
role
pathogenesi
rhd
protein
coiledcoil
surfac
protein
consist
hypervari
aminotermin
region
highli
conserv
sequenc
ident
carboxytermin
crepeat
region
fig
function
protein
import
prevent
bacteri
clearanc
complementmedi
phagocytosi
limit
host
defens
mechan
previou
studi
indic
protect
immun
ga
evok
opson
antibodi
serotyp
epitop
aminotermin
region
mtype
specif
combin
vaccineadjuv
deliveri
system
offer
potenti
mucos
vaccin
deliveri
exampl
lipidcorepeptid
lcp
system
novel
synthet
selfadjuv
vaccin
deliveri
system
incorpor
adjuv
prr
agonist
carrier
antigen
peptid
vaccin
singl
molecular
entiti
fig
system
previous
shown
effici
deliv
ga
vaccin
induc
immun
evid
suggest
adjuv
activ
lcp
involv
induct
dc
activ
three
approach
current
investig
develop
subunit
ga
vaccin
base
protein
multival
ga
vaccin
multival
approach
employ
combin
aminotermin
protein
fragment
repres
differ
type
design
target
preval
ga
strain
popul
use
approach
recombin
multival
ga
vaccin
contain
protein
peptid
differ
ga
serotyp
preval
north
america
demonstr
evok
opson
antibodi
anim
epidemiolog
data
vaccin
would
cover
major
pharyng
invas
ga
diseas
includ
rf
invas
fasciiti
toxic
shock
syndrom
recent
new
ga
vaccin
shown
immunogen
rabbit
evok
opson
antibodi
nonvaccin
serotyp
potenti
creat
vaccin
much
broader
coverag
type
vaccin
popul
specif
therefor
may
effect
univers
may
also
need
redesign
period
reflect
chang
epidemiolog
ga
infect
vaccin
ga
vaccin
employ
peptid
epitop
conserv
crepeat
region
protein
second
approach
potenti
theori
greater
coverag
type
immun
mice
cregion
peptid
ga
vaccin
candid
call
conjug
carrier
protein
diphtheria
toxoid
dt
codeliveri
appropri
adjuv
led
protect
system
mucos
ga
infect
fig
also
elicit
protect
immun
ga
link
lipopeptid
studi
shown
intranas
immun
mice
cregion
peptid
conjug
experiment
mucos
adjuv
cholera
toxin
b
subunit
ctb
evok
protect
immun
ga
mucos
level
ctb
could
possibl
enter
olfactori
region
central
nervou
system
caus
neuron
damag
follow
intranas
deliveri
therefor
suitabl
human
use
vector
deliveri
approach
includ
express
crepeat
region
vaccinia
viru
commens
bacterium
lactococcu
lacti
streptococcu
gordonii
third
combin
vaccin
approach
use
serotyp
conserv
protein
peptid
epitop
initi
heteropolym
ga
vaccin
construct
synthes
free
radicalinduc
polymer
acryloyl
peptid
combin
seven
serotyp
epitop
highli
conserv
cregion
peptid
epitop
call
type
target
heteropolym
repres
ga
infect
preval
northern
territori
australia
region
highli
endem
ga
immun
mice
heteropolym
demonstr
excel
immunogen
protect
homolog
heterolog
ga
strain
indic
potenti
provid
broad
coverag
howev
batchtobatch
variat
led
alter
immun
respons
limit
applic
human
use
vaccin
also
requir
addit
adjuv
effect
limit
use
mucos
vaccin
due
lack
safe
effect
mucos
adjuv
later
multiepitop
ga
vaccin
candid
synthes
base
lcp
system
induc
highli
opson
antibodi
follow
parenter
deliveri
mice
well
protect
mucos
ga
infect
follow
intranas
immun
fig
main
concern
use
larg
region
protein
ga
vaccin
potenti
induc
autoimmun
respons
due
immunolog
crossreact
host
protein
therefor
import
identifi
protect
antigen
determin
separ
biolog
relev
epitop
host
tissu
crossreact
potenti
harm
epitop
map
studi
use
identifi
conserv
ga
vaccin
candid
contain
conform
protect
b
cell
epitop
design
lack
human
heart
crossreact
cell
epitop
